HK:1513 Livzon Pharmaceutical Group Inc

Livzon Pharmaceutical Group Inc. engages in the research and development, production, and sale of pharmaceutical products in the People's Republic of China. Its products primarily include Chinese and Western drug preparation products, such as Shengqi Fuzheng Injection, a series of Bismuth Potassium Citrate Granules products, anti-viral granules, Urofollitropin for injection, Menotropins for injection, Ilaprazole, Voriconazole for injection, mouse nerve growth factor for injection, and Leuprorelin Acetate Microspheres for injection. The company's products also comprise bulk medicines and intermediates, including Pravastatin, Salinomycin, Mevastatin, Colistin, Phenylalanine, Ceftriaxone Sodium, Cefuroxime Sodium, and Cefodizime Sodium; and diagnostic reagent products, such as ELISA HIV testing reagent, MYCOII testing reagent, and TPPA testing reagent. In addition, the company provides chemical drugs, biochemical drugs, microbiological preparations, and antibiotics; polypeptide bulk medicines; human menopausal gonadotropin and human chorionic gonadotropin medicines; Omeprazole Sodium for injection; Ranitidine Bismuth Citrate tablets; Valaciclovir Hydrochloride tablets; Fluvoxamine Maleate tablet; Perospirone Hydrochloride tablets; and Prostant used for the treatment of clearing away heat evil and promoting diuresis. Further, it offers specialist bulk medicines and intermediates, as well as diagnostic reagents and equipment. Livzon Pharmaceutical Group Inc. was founded in 1985 and is based in Zhuhai, China.

22.80 HKD
As of 08/12/2022

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Emerging markets
GICS sector:  Health Care
Index country:  China
Country of incorporation:  China
IPO date:  01/16/2014
Stock exchange:    Hong Kong Exchange
Exchange country:   Hong Kong
Market cap:   0 HKD
Current dividend yield:   0.00%
Sedol:      BJ34614

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy